| Zhang, Huilai |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
NCT06149169: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma |
|
|
| Active, not recruiting | 2 | 10 | RoW | CD19-targeted Chimeric Antigen Receptor(CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | 10/24 | 03/25 | | |
NCT05590221: Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide | Peking University Cancer Hospital & Institute, Shanghai Ming Ju Biotechnology Co., Ltd. | B-cell Lymphoma | 02/24 | 12/24 | | |
| Recruiting | 2 | 12 | RoW | Relma-cel, CD19-targeted Chimeric Antigen Receptor(CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Non-Hodgkin Lymphoma, Large B-cell Lymphoma | 04/25 | 12/26 | | |
NCT05245916: IBI397 or Combination Therapies in Patients With Advanced Malignancies |
|
|
| Withdrawn | 1a/1b | 30 | RoW | IBI397, IBI397+Sintilimab, IBI397+Rituximab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 08/23 | 08/23 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT06395870: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1 | 33 | RoW | LUCAR-G39D cells product | Tianjin Medical University Cancer Institute and Hospital, Nanjing Legend Biotech Co. | B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory | 06/26 | 06/28 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
